ADJACENT COMPOUND GUIDE

What Is NAD+?

NAD+ is nicotinamide adenine dinucleotide, a natural molecule used by every living human cell. It helps enzymes transfer electrons during energy metabolism and supplies material for reactions involved in DNA repair, immune signalling and cellular regulation.

NAD+ is not a peptide. It is a dinucleotide, meaning a molecule assembled from two nucleotide-related units. Orentra includes it as an adjacent compound because injectable NAD+ and NAD-related products are frequently offered alongside research peptides.

Research statusEndogenous coenzyme with limited direct treatment evidence
Compound classDinucleotide coenzyme, not a peptide
Biological roleEnergy metabolism and cellular signalling
Treatment evidenceLimited direct human evidence
Last reviewedSeptember 2026
THE SHORT ANSWER

NAD+ is essential biology, but an essential molecule is not automatically an effective treatment. Human research has shown that NAD+ metabolism can be measured and altered. It has not established intravenous NAD+ as a general treatment for ageing, fatigue, addiction, mental clarity or recovery. A 2019 infusion study described how six healthy men processed NAD+ during a six-hour infusion, but it had no placebo group and did not test a clinical benefit. A 2026 retrospective clinic study mainly examined tolerability, not whether intravenous NAD+ improved health. The FDA has received reports of severe chills, shaking, vomiting and fatigue after compounded NAD+ injections, including reactions associated with excessive endotoxin.

What does NAD+ stand for?

Nicotinamide is a form of vitamin B3. Adenine is one of the chemical bases used in DNA and cellular energy molecules. Dinucleotide refers to the two linked nucleotide units.

The plus sign shows that the molecule is in its oxidised form. NAD+ can accept electrons and a hydrogen ion to become NADH, its reduced form. Oxidation and reduction are paired chemical processes involving the transfer of electrons.

Cells cycle between NAD+ and NADH. This redox pair helps move energy from food into pathways that make adenosine triphosphate, or ATP. ATP is often described as a cell's energy currency because it supplies energy for many cellular processes.

What is NAD+ made from?

NAD+ contains two nucleotide-related parts joined through their phosphate groups. One contains adenine. The other contains nicotinamide. Ribose sugars and phosphate groups complete the structure.

The body makes NAD+ from several dietary starting points:

  • tryptophan, an essential amino acid;
  • nicotinic acid, also called niacin;
  • nicotinamide;
  • nicotinamide riboside, shortened to NR;
  • nicotinamide mononucleotide, shortened to NMN.

These starting substances enter different biosynthetic routes. Biosynthesis means making a molecule through enzyme-controlled reactions in living cells. The salvage pathway recycles nicotinamide back into NAD+. “Salvage” here means reuse, not rescue from an emergency.

NAD+ is also consumed. Enzymes called sirtuins, poly(ADP-ribose) polymerases and CD38 use it in signalling reactions. Poly(ADP-ribose) polymerases, normally shortened to PARPs, participate in responses to DNA damage. CD38 is an enzyme on many immune and other cells that breaks down NAD+-related molecules.

When was NAD+ first documented?

The history begins before the name NAD existed. In 1906, Arthur Harden and William John Young reported a heat-stable factor needed for fermentation in yeast extracts. Fermentation is the process by which yeast converts sugar while releasing energy.

Hans von Euler-Chelpin later helped identify the chemical nature of this cofactor. In the 1930s, Otto Warburg's work clarified its role in hydrogen transfer during metabolic reactions. The molecule was historically called diphosphopyridine nucleotide before nicotinamide adenine dinucleotide became standard.

Research later established NAD+ as both a redox coenzyme and a consumed substrate in signalling reactions. Interest in ageing grew after animal studies connected NAD+ metabolism with sirtuins, DNA repair and age-related cellular changes.

PeriodDevelopment
1906Harden and Young described a heat-stable factor required for yeast fermentation
1930sChemical and redox roles were clarified
Mid twentieth centuryNAD+/NADH became central to the modern account of cellular metabolism
1990s and 2000sNAD+-consuming signalling enzymes and ageing-related pathways received greater attention
2019A six-person pilot described blood and urine metabolites during a six-hour NAD+ infusion
2026New human studies added pharmacokinetic and tolerability data, while whole-blood research challenged a simple age-related decline

How is NAD+ manufactured?

Commercial NAD+ can be made through chemical synthesis, enzymatic synthesis or fermentation-based processes. Enzymatic synthesis uses purified enzymes to assemble or convert starting materials under controlled conditions. Fermentation uses living microorganisms that have the required metabolic machinery.

One enzymatic route converts nicotinamide mononucleotide and ATP into NAD+ using an enzyme called nicotinamide mononucleotide adenylyltransferase. Other systems recycle ATP or use genetically modified microorganisms to improve yield.

Raw materials can include nicotinamide-related precursors, adenine-containing nucleotides, phosphate donors, water, buffers and enzymes. If microorganisms are used, culture nutrients and processing aids are also involved. The product must then be separated from proteins, cells, salts, solvents and chemically related molecules.

Chromatography and spectroscopy can confirm identity and chemical purity. Injectable manufacture requires much more: sterile processing, endotoxin limits, particulate testing, validated strength, stability and container compatibility. A dietary-supplement-grade powder is not automatically suitable for making a sterile injection.

The FDA has specifically warned compounders to use ingredients suitable for sterile compounding after adverse reactions to compounded NAD+ made with ingredient containing excessive endotoxin. Endotoxins are bacterial components that can trigger severe inflammatory reactions even if no living bacteria remain.

What does NAD+ do in energy metabolism?

When carbohydrates, fats and proteins are broken down, enzymes transfer electrons to NAD+, forming NADH. NADH carries those electrons to the mitochondrial respiratory chain. Mitochondria are cell structures that use an electron-transfer system to help make ATP.

NADH eventually gives up its electrons and returns to NAD+. A cell needs both forms and the ability to cycle between them. Simply measuring a total amount does not describe the redox balance in every organ or cellular compartment.

NAD+ also works outside mitochondria. It participates in glycolysis, the pathway that breaks down glucose in the cell fluid, and in many biosynthetic reactions. A severe NAD+ deficiency would disrupt fundamental biology. This does not mean that raising blood NAD+ above an unknown baseline improves energy in a healthy person.

What does NAD+ do in signalling and DNA repair?

PARP enzymes use NAD+ while helping cells respond to DNA damage. Sirtuins remove chemical groups from proteins and use NAD+ in the process. CD38 and related enzymes produce signalling molecules that influence calcium movement and immune function.

These pathways explain why NAD+ is studied in ageing and disease. They also show why the biology is not a simple “more is better” system. NAD+ production, location and consumption are tightly regulated. Increasing one measured pool might not improve the pathway of interest and could affect other processes.

DNA repair in a laboratory model is not the same as preventing cancer or slowing human ageing. A biomarker change is a change in a measurable biological feature. It is not a clinical benefit unless research connects it to how a person feels, functions or survives.

Does NAD+ decline with age?

Animal tissues often show age-related changes in NAD+ metabolism. Human evidence is less consistent and depends on which tissue, chemical form and measurement method are used.

Some human studies have reported lower NAD+-related measurements with age or disease. Others have not. A 2022 study of 1,518 people found an age association in men but not women. Differences in sampling, storage and laboratory methods can affect results because NAD-related molecules are chemically unstable.

In 2026, researchers measured whole-blood NAD+ in healthy adults across a wide age range and did not find an age-related decline or a clear effect of lifestyle interventions. An accompanying commentary argued that whole-blood NAD+ does not provide a simple measure of healthy ageing.

This does not prove that no human tissue changes with age. Whole blood is not brain, muscle or liver. It does show that the phrase “NAD+ always falls as we age” is too broad.

What was studied in the 2019 NAD+ infusion pilot?

The 2019 study enrolled six healthy men. Participants received NAD+ intravenously for six hours at 3 micromoles per minute. A micromole is one millionth of a mole, a unit used to count molecules. Researchers took blood and urine samples during and after the infusion.

The study described how NAD+ and related metabolites changed. Much of the infused NAD+ did not appear immediately as intact NAD+ in plasma during the early part of the infusion, while breakdown products changed in blood and urine. The findings suggested rapid metabolism and helped generate questions about how infused NAD+ is processed.

The study was not randomised and had no placebo group. It was not designed to show improved energy, cognition, withdrawal symptoms or ageing. Six healthy men are too few to establish safety across a wider population.

Study design, not dosing guidance

The six-hour duration and 3-micromole-per-minute infusion rate describe one exploratory pharmacokinetic study. Pharmacokinetics is the study of how the body absorbs, distributes, changes and removes a substance. The level is included to show what researchers actually examined, not to provide a treatment protocol.

What did the 2026 intravenous tolerability study find?

A 2026 retrospective study compared clinic records from people who had received intravenous NAD+ or intravenous nicotinamide riboside. Retrospective means the researchers looked back at existing records rather than assigning treatments in advance.

The study focused mainly on infusion experience and recorded symptoms. It was not a randomised efficacy trial, and the groups were not created by chance. Clinic selection, incomplete recording and differences between patients can influence the results.

The paper provides useful information about how these infusions were tolerated in that setting. It does not show that either treatment improves ageing, fatigue or disease. A tolerability observation and a clinical benefit are different questions.

Can the body use NAD+ given from outside?

Intact NAD+ is a relatively large, charged molecule. It does not freely cross every cell membrane. Enzymes outside cells can break it into smaller components, which may then be transported and reused.

Different tissues express different transporters and enzymes. Researchers have reported direct NAD+ transport in some settings, but this does not establish uniform delivery to every human organ. Intravenous administration puts material into the bloodstream; it does not guarantee that intact NAD+ reaches brain or muscle cells in a useful amount.

Oral NAD+ faces additional questions about digestion and absorption. A blood biomarker after an oral formulation can show biological exposure, but it must still be connected to a meaningful health outcome.

Are NAD+ precursors the same as NAD+ infusions?

No. Nicotinamide, nicotinic acid, NR and NMN are starting materials the body can use to make NAD+. Their absorption and metabolism differ from direct intravenous NAD+.

Human trials of a precursor cannot be used as direct evidence for an NAD+ infusion. The reverse is also true. Even when both raise a measured NAD-related marker, the route, metabolites and tissue exposure may differ.

Several precursor studies show that blood NAD+ can increase. Clinical benefits have been less consistent. Reviews generally conclude that human evidence is still developing and does not support broad anti-ageing claims.

Does NAD+ improve energy or fatigue?

No controlled programme has established intravenous NAD+ as a general treatment for fatigue or low energy. Fatigue can be caused by sleep loss, anaemia, thyroid disease, infection, heart or lung disease, medication effects, depression and many other conditions.

Because NAD+ participates in energy metabolism, it is tempting to assume that extra NAD+ creates extra energy. Cellular pathways do not work like filling a fuel tank. The limiting factor may be oxygen delivery, mitochondrial disease, nutrition, hormones or another enzyme entirely.

Does NAD+ improve cognition or brain health?

Animal and cell research links NAD+ metabolism with nerve-cell health, inflammation and mitochondrial function. These findings do not show that an infusion improves memory, concentration or neurodegenerative disease in people.

Cognitive outcomes require validated tests and appropriate comparison groups. Feeling more alert during or after a clinic visit is not enough to separate treatment effects from expectation, rest, hydration or other parts of an infusion.

Does NAD+ treat addiction or withdrawal?

NAD+ infusions are sometimes promoted for alcohol or drug withdrawal. Dependence and withdrawal are medical conditions involving specific risks, including seizures, delirium, dehydration and relapse.

No robust controlled clinical evidence establishes intravenous NAD+ as a treatment for substance-use disorder or acute withdrawal. Testimonials and uncontrolled clinic series cannot show how NAD+ compares with established care.

Does NAD+ slow ageing?

No intervention has shown that intravenous NAD+ slows human ageing or extends human lifespan. Animal work on NAD-related pathways is scientifically important, but ageing involves many interacting processes.

A treatment would need to improve meaningful outcomes, not only move a molecular marker. It would also need long-term safety evidence. At present, the human evidence does not meet that standard.

What are the safety concerns?

Risks come from the molecule, the rate and route of exposure, the finished product and the infusion procedure. Reported experiences include nausea, abdominal discomfort, headache, flushing and chest discomfort, although good comparative data are limited.

The FDA reported severe chills, shaking, vomiting and fatigue after compounded injectable NAD+. Some patients needed medical treatment. Investigation found excessive bacterial endotoxin in ingredient used to compound the products.

Sterile compounded products can also carry risks of microbial contamination, incorrect strength and particulates. Intravenous access can cause infection, inflammation of the vein and fluid-related problems. These procedure risks exist even if the active ingredient is chemically correct.

People with serious illness may be more vulnerable to disturbances in fluid balance or infusion reactions. The absence of a comprehensive approved label means there is no regulator-reviewed account of contraindications, interactions and adverse-event rates for a finished NAD+ infusion medicine.

Is NAD+ approved as an anti-ageing infusion?

No. NAD+ is a natural cellular molecule and appears in research and compounded products, but there is no FDA-approved NAD+ infusion for anti-ageing, energy, cognition, addiction recovery or general wellbeing.

Compounded drugs are not FDA approved. The FDA does not review their safety, effectiveness or manufacturing quality before they are supplied in the same way it reviews an approved medicine.

What benefits are claimed, and what does the evidence support?

ClaimWhat the evidence supports
Raises cellular energyNAD+ is essential to energy metabolism; no established general energy treatment benefit
Reverses ageingNo human evidence
Improves cognitionMechanistic and animal interest; no established clinical benefit from direct NAD+ treatment
Treats fatigueNo robust controlled evidence for a general fatigue indication
Treats addiction or withdrawalNo dependable evidence supporting replacement of established care
Repairs DNANAD+ participates in DNA-damage responses; an infusion has not been shown to repair people or prevent disease
Is harmless because it is naturalNot supported; route, exposure and product quality create risks

What research would be needed next?

Trials would need a defined pharmaceutical formulation, validated purity and sterility, and pharmacokinetic work explaining what reaches blood and tissues. They would then need to test a specific condition rather than “wellness”.

A useful trial would randomly assign participants to NAD+ or a matched placebo, keep participants and assessors unaware of assignment where possible, define outcomes in advance and report adverse events. Longer follow-up would be needed for claims about ageing or chronic disease.

Why is NAD+ difficult to measure?

NAD+ and related molecules can change after a sample is taken. Time, temperature, cell breakage and the chemicals used to prepare blood or tissue can alter the result. Plasma, whole blood and isolated blood cells are not equivalent samples.

Whole blood contains large numbers of red blood cells, which have their own NAD metabolism. A whole-blood result may therefore be driven by cell composition rather than the NAD+ level in muscle, liver or brain.

Laboratories use methods such as enzymatic cycling assays and liquid chromatography with mass spectrometry. Different methods may measure free NAD+, total NAD-related material or several metabolites. Results from one method should not be compared with another without checking the sample and units.

This measurement problem helps explain why human age studies disagree. It also means that a clinic's “NAD test” needs validation before it can guide treatment.

What is the difference between a biochemical effect and a clinical benefit?

An infusion can change a blood or urine metabolite without improving a person's health. The metabolite result shows that the body encountered and processed the substance. It does not show better energy, memory or lifespan.

A clinical benefit is an improvement in how a person feels, functions or survives. Depending on the condition, examples might include validated fatigue scores, ability to walk, relapse rate or hospital admission.

Trials should choose the main clinical outcome before analysing data. If researchers measure dozens of metabolites, some may change by chance. Those findings are useful for generating hypotheses but need confirmation.

How should the evidence for direct NAD+ and precursors be separated?

InterventionWhat reaches the body firstMain human evidence question
Intravenous NAD+NAD+ directly in the bloodstreamHow quickly it is broken down, tolerability and whether any clinical benefit follows
Oral NAD+NAD+ entering the digestive systemWhether intact or broken-down components are absorbed and useful
Nicotinamide ribosideA precursor that cells can convertWhether tissue NAD+ changes and whether that improves outcomes
Nicotinamide mononucleotideAnother NAD+ precursorAbsorption, conversion, tissue effects and clinical relevance
Niacin or nicotinamideEstablished vitamin B3 formsCorrection of deficiency and dose-specific effects, with known high-exposure risks

Results cannot be moved freely between these categories. A precursor may raise blood NAD+ through normal biosynthesis without reproducing the exposure created by an infusion.

What did the 2026 oral NAD+ trial add?

A small randomised Phase 0/1b study in adults aged 45 to 75 examined five days of a specially formulated oral NAD+ product. Phase 0/1b describes exploratory early research focused on biological exposure and initial tolerability rather than proof of treatment benefit.

The study reported changes in whole-blood intracellular NAD+ and metabolic tracing. It was short and used a proprietary formulation. It did not show that ordinary oral NAD+ products improve ageing, cognition or disease.

Retrospective registration and commercial involvement are relevant when weighing the result. Neither invalidates a study, but independent replication and prospectively registered longer trials would strengthen confidence.

Why can infusion reactions be hard to interpret?

Symptoms during an infusion can arise from the active substance, its breakdown products, the rate of administration, the fluid volume, an excipient or contamination. An excipient is an inactive formulation ingredient such as a buffer or preservative.

Endotoxin reactions can cause shaking, fever, low blood pressure, nausea and severe illness. These symptoms can be mistaken for an expected “detox” response. There is no sound medical basis for treating severe infusion symptoms as evidence that a wellness product is working.

A controlled trial uses a defined product and records the timing, severity and management of every adverse event. Spontaneous reports are valuable warnings but usually cannot calculate how often a problem occurs because the total number exposed is unknown.

What does regulation of compounded NAD+ mean?

Compounding is the preparation of a medicine for an individual or a limited clinical need when an approved product does not meet that need. In the United States, sections 503A and 503B of federal law set different conditions for traditional pharmacies and outsourcing facilities.

Compounded products are not FDA approved. The agency does not assess each finished formula for safety and effectiveness before supply. Facilities still have legal quality obligations, especially for sterile products.

The 2026 FDA warning letter to GenoGenix stated that NAD+ and 5-Amino-1MQ were not eligible bulk substances for the firm's section 503B compounding. The letter also described reports of low blood pressure, uncontrollable shaking, shivering and body aches in three patients receiving a compounded NAD+ product. A warning letter records regulatory findings, not a clinical trial, but it is relevant to real product risk.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is NAD+ a peptide?

No. It is a dinucleotide coenzyme, not a chain of amino acids.

Is NAD+ the same as NADH?

They are two redox forms of the same coenzyme system. NAD+ accepts electrons to become NADH.

Does NAD+ decline with age?

Some tissues and studies show age-related changes, but human results are not uniform. A 2026 study found that whole-blood NAD+ did not vary with age in its participants.

Do NAD+ infusions work?

Human studies have described metabolism and tolerability, but have not established broad clinical benefits for ageing, fatigue, cognition or recovery.

Is intravenous NAD+ safe?

An adequate safety profile has not been established for a general infusion treatment. The FDA has reported serious reactions to compounded NAD+ products associated with excessive endotoxin.

Is NAD+ FDA approved for anti-ageing?

No.

Are NR and NMN the same as NAD+?

No. They are NAD+ precursors, meaning starting substances the body can use to make NAD+.

What did the 2019 infusion study prove?

It described blood and urine metabolite changes in six healthy men. It did not test or prove a health benefit.

Research reviewed through September 2026.